110
Participants
Start Date
July 31, 2009
Primary Completion Date
March 31, 2013
Study Completion Date
March 31, 2013
brentuximab vedotin
Every 3 weeks by IV infusion (1.2 or 1.8 mg/kg) until disease progression, unacceptable toxicity, or study closure
NYU Clinical Cancer Center, New York
Columbia University Medical Center, New York
University of Miami Miller School of Medicine / Sylvester Comprehensive Cancer Center, Miami
Nationwide Children's Hospital, Columbus
St. Francis Medical Group Oncology & Hematology Specialists, Indianapolis
Karmanos Cancer Institute / Wayne State University, Detroit
Loyola University Medical Center - Cardinal Bernadin Cancer Center, Maywood
Washington University School of Medicine, St Louis
Charles A. Sammons Cancer Center, Dallas
Hopital Saint-Louis/Service d'Hematologie, Paris
MD Anderson Cancer Center /The University of Texas, Houston
Colorado Blood Cancer Institute, Denver
City of Hope National Medical Center, Duarte
Stanford Cancer Center, Stanford
University of Alabama at Birmingham, Birmingham
The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack
Seattle Cancer Care Alliance / University of Washington Medical Center, Seattle
Collaborators (1)
Millennium Pharmaceuticals, Inc.
INDUSTRY
Seagen Inc.
INDUSTRY